Elranatamab in Relapsed/Refractory Multiple Myeloma
NCT06711705
·
clinicaltrials.gov ↗
PHASE2
Phase
RECRUITING
Status
33
Enrollment
OTHER
Sponsor class
Conditions
Multiple Myeloma
Interventions
DRUG:
Elranatamab
Sponsor
University of California, San Diego